Alfred Wieder

Alfred Wieder AG was a German financial services company that played a pivotal role in the European biotechnology landscape as the founding investor in BioNTech SE. Established by Alfred Wieder in 2004, the firm specialized in the distribution of venture capital through the MIG Fonds, which provided critical early-stage funding for innovative life science companies. Beyond its landmark investment in BioNTech's mRNA platform, the company facilitated capital for other notable entities such as Ganymed Pharmaceuticals and Affimed. Although the firm did not develop its own therapeutic pipeline, its financial backing was essential for the advancement of novel treatments in oncology and infectious diseases. The company was later renamed to MIG Service AG and its functions were integrated into the broader MIG AG investment group.